Dr. Andreas Hermann
Professor
Center for Neurodegenerative Diseases
German Centre for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen)
Germany
Biography
Andreas Hermann is clinician scientist with main focus on the bidirectional translation between basic science and clinical patient work. His initial studies were on the regenerative capacity of the adult midbrain using various murine and human stem cell models. Main topics of his work now are human cell models of rare neurodegenerative diseases (iPS cells) for disease modelling and drug development approaches. Patient-centered care with main focus on advances stages of neurodegenerative diseases and palliative care research are additional focus of his group. 2011-2014 Habilitation, Technische Unviersität Dresden (TUD) 2009-2011 MD thesis, Technische Unviersität Dresden (TUD) 2003-2007 PhD thesis, University of Ulm Appointments Since 2016 Head of the Division for Neurodegenerative Diseases, Dept. Neurology, Technische Universität Dresden (TUD), Dresden Since 2016 Deputy Director, Center for Healthy Aging, TUD, Dresden 2013-2016 Seniour neurologist, Dept. Neurology, TUD, Dresden 2005-2013 Resident neurology, Dept. Neurology, TUD, Dresden 2007-2011 Post doc, DFG-Research Center for Regenerative Therapies Dresden (CRTD), TUD, Dresden
Research Interest
A main focus of the Clinical Cooperation Unit is the bidirectional translation between basic science and clinical patient work, including human patient-derived iPSC cultures, drug development, biomarker development (MRI markers and behavioral endophenotypes); characterization of prodromal states of neurodegeneration and clinical correlation of spreading of disease pathology including non motor symptoms in neurodegenerative diseases. Future direction will more and more involve work on healthy aging including modes and mechanisms of disease converions from prodromal stages or interventions to avoid secondary aging.
Publications
-
Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Lojewski X*, Staropoli JF* et al., and Hermann A*, Cotman S*. Hum Mol Gen 2014, Apr 15;23(8):2005-22.
-
Stepwise acquirement of hallmark neuropathology in FUS-ALS iPSC models depends on mutation type and neuronal aging. Japtok J, Lojewksi X et l., and Hermann A. Neurobiol Dis. 2015 Oct;82:420-9.
-
Eyetracking-based assessment suggests preserved wellbeing in locked-in patients. Linse K, Rüger W, Joos M, Schmitz-Peiffer H, Storch A, Hermann A. Ann Neurol. 2017 Feb;81(2):310-315.